Abstract-We investigated whether activation of A 1 or A 3 adenosine receptors (ARs) induces late preconditioning (PC) against infarction in conscious rabbits using the selective AR agonists 2-chloro-N 6 -cyclopentyladenosine (CCPA) and N 6 -3-iodobenzyladenosine-5Ј-N-methylcarboxamide (IB-MECA). In vitro radioligand binding and cAMP assays demonstrated CCPA to be Ϸ200-to 400-fold selective for the rabbit A 1 AR and IB-MECA to be Ϸ20-fold selective for the rabbit A 3 AR. We observed that (1) pretreatment of rabbits 24 hours earlier with CCPA (100 g/kg IV bolus) or IB-MECA (100 or 300 g/kg) resulted in an Ϸ35% to 40% reduction in the size of the infarct induced by 30 minutes of coronary artery occlusion and 72 hours of reperfusion compared with vehicle-treated rabbits, whereas pretreatment with the selective A 2A AR agonist CGS 21680 (100 g/kg) had no effect; (2) the delayed cardioprotective effect of CCPA, but not that of IB-MECA, was completely blocked by coadministration of the highly selective A 1 AR antagonist N-0861; (3) inhibition of nitric oxide synthase (NOS) with N -nitro-L-arginine during the 30-minute occlusion abrogated the infarct-sparing action of CCPA but not that of IB-MECA; and (4) inhibition of ATP-sensitive potassium (K ATP ) channels with sodium 5-hydroxydecanoate during the 30-minute occlusion blocked the cardioprotective effects of both CCPA and IB-MECA. Taken together, these results indicate that activation of either A 1 ARs or A 3 ARs (but not A 2A ARs) elicits delayed protection against infarction in conscious rabbits and that both A 1 AR-and A 3 AR-induced cardioprotection involves opening of K ATP channels. However, A 1 AR-induced late PC uses an NOS-dependent pathway whereas A 3 AR-induced late PC is mediated by an NOS-independent pathway. -cyclopentyladenosine (CCPA) limited infarct size after a 30-minute coronary artery occlusion produced 24 to 72 hours later. On the other hand, we found in conscious rabbits that a 24-hour pretreatment with CCPA did not attenuate myocardial stunning. 2 One interpretation of these results is that stimulation of ARs is capable of inducing late PC against infarction, but not late PC against myocardial stunning. This hypothesis is not implausible, because myocardial infarction and myocardial stunning are pathophysiologically distinct. 3, 4 However, since the studies by Baxter et al 1 were performed in open-chest, anesthetized rabbits whereas our studies were performed in conscious rabbits, differences in the model systems that were used is another potential explanation for the disparate results. Given
A lthough it is well established that stimulation of adenosine receptors (ARs) can induce early preconditioning (PC), it is controversial whether ARs can elicit the late phase of PC. -cyclopentyladenosine (CCPA) limited infarct size after a 30-minute coronary artery occlusion produced 24 to 72 hours later. On the other hand, we found in conscious rabbits that a 24-hour pretreatment with CCPA did not attenuate myocardial stunning. 2 One interpretation of these results is that stimulation of ARs is capable of inducing late PC against infarction, but not late PC against myocardial stunning. This hypothesis is not implausible, because myocardial infarction and myocardial stunning are pathophysiologically distinct. 3, 4 However, since the studies by Baxter et al 1 were performed in open-chest, anesthetized rabbits whereas our studies were performed in conscious rabbits, differences in the model systems that were used is another potential explanation for the disparate results. Given the lack of uniformity of the studies described above, the ability of ARs to induce late PC remains uncertain.
Of the four subtypes of ARs known to exist (A 1 , A 2A , A 2B , and A 3 ), it is generally thought that the A 1 AR subtype is responsible for mediating the cardioprotective effects of adenosine. 5 There is increasing evidence, however, that A 3 ARs may also exert cardioprotection. 6 -10 Evidence in support of this hypothesis includes the observations that early PC is not blocked by selective A 1 AR antagonists but is blocked by nonselective antagonists at high concentrations capable of blocking the A 3 AR, suggesting that the A 3 AR can also induce early PC. 6, 9 Furthermore, activation of A 3 ARs has been suggested to reduce injury in several different models of ischemia/reperfusion injury. 7, 8, 10 Based on these results, it has been hypothesized that A 3 ARs are also expressed in ventric-ular cardiomyocytes and that they provide protection via a similar mechanism as A 1 ARs. The role of A 3 ARs in late PC, however, is unknown.
The present study was undertaken to address these issues and to further characterize the cardioprotective actions of AR stimulation. The results demonstrate, for the first time, that activation of A 1 and A 3 ARs induces late PC against infarction via different mechanisms.
Materials and Methods

Radioligand Binding Assays and cAMP Assays
Binding assays were performed with membranes prepared from HEK 293 cells expressing recombinant rabbit A 1 ARs or A 3 ARs using N 6 -(4-amino-3-[ 125 I]iodobenzyl)adenosine-5Ј-N-methylcarboxamide ([   125   I ]AB-MECA) as the radioligand. The rabbit A 1 AR cDNA used for transfections was as described by Bhattacharya et al, 11 and the rabbit A 3 AR cDNA was cloned from a rabbit brain cDNA library. Additional binding assays with [
125 I]AB-MECA were performed with membranes prepared from rabbit brain and spleen. Inhibition of isoproterenol-induced cAMP accumulation by adenosine agonists was performed on HEK 293 cells expressing rabbit A 1 ARs or A 3 ARs using radioimmunoassay.
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Analysis
mRNA expression of A 1 ARs and A 3 ARs was determined by RT-PCR of total RNA obtained from rabbit heart or 100 to 200 ventricular rabbit cardiomyocytes isolated by enzymatic digestion.
Studies in Conscious Rabbits
New Zealand White rabbits (2.2 to 2.9 kg; Myrtle's Rabbitry, Thompson Station, Tenn) were instrumented with a balloon occluder around a major branch of the left coronary artery for occlusion and reperfusion and bipolar ECG leads on the chest wall. In some studies (groups I through IV; see below), a Doppler thickening crystal was sutured to the epicardial surface of the region at risk to measure wall thickening (WTh). The rabbits were allowed to recover for a minimum of 10 days after surgery. All animal experiments conformed to the guidelines established by the University of Louisville.
The experimental protocol is depicted in Figure 1 . All rabbits were subjected to 30 minutes of coronary artery occlusion and 3 days of reperfusion. At the end of the experiments, infarct size and the area-at-risk size were measured by dual staining with phthalo blue dye and triphenyltetrazolium hydrochloride. Rabbits were randomly assigned to 12 treatment groups. Group I (control group) received 1 mL of vehicle as an IV bolus 24 hours before the occlusion. In groups II, III, and IV, CCPA (100 g/kg), CGS-21680 (100 g/kg; A 2A receptor agonist), or IB-MECA (100 g/kg or 300 g/kg) were given as boluses 24 hours before the coronary occlusion. Groups V and VI were treated 24 hours before the occlusion with N-0861 (7.5 mg/kg IV bolus followed immediately by an intravenous infusion of 0.3 mg · kg -1 · min -1 , which was maintained for 3 hours; total dose, 55.5 mg/kg); 5 minutes after the bolus injection of N-0861, the rabbits were treated with either CCPA (100 g/kg IV bolus) or IB-MECA (300 g/kg IV bolus). Groups VII, VIII, and IX were given N -nitro-L-arginine (L-NA) (13 mg/kg as an IV bolus) and groups X, XI, and XII were given 5-hydroxydecanoate (5-HD) (5 mg/kg IV bolus) 5 minutes before the 30-minute occlusion in rabbits pretreated 24 hours earlier with either CCPA (100 g/kg IV bolus; groups VII and X), IB-MECA (300 g/kg IV bolus; groups VIII and XI), or vehicle (groups IX and XII).
An expanded Materials and Methods section can be found in an online data supplement available at http://www.circresaha.org.
Results
Pharmacological Characterization of Rabbit A 1 ARs and A 3 ARs
Because the pharmacology of A 3 ARs differs markedly among species, 12 preliminary studies were performed to characterize rabbit A 1 ARs and A 3 ARs using radioligand binding analysis and functional assays. follows: (1) CCPA is a potent and selective agonist for recombinant rabbit A 1 ARs (377-fold); (2) IB-MECA is a potent A 3 AR agonist; however, it is only 21-fold selective versus the A 1 AR; (3) like rodent A 3 ARs, 13 the rabbit A 3 AR is resistant to blockade by xanthine antagonists and no selective antagonists were identified; (4) the xanthine and adenine antagonists had high affinity for the A 1 AR, therefore useful A 1 selective antagonists were identified including CPX (7750-fold) and N-0861 (1400-fold); and (5) 12 and that the brain is a rich source of A 1 ARs. These studies could not be performed in heart, because the level of expression of all of the adenosine receptor subtypes is too low to be detected accurately in heart tissue with agonist radioligands. For these studies, binding to A 1 ARs was defined by specific binding displaced by 500 nmol/L CPX, A 3 AR binding was defined by the difference in specific binding displaced by 500 nmol/L CPX and 500 nmol/L MRS 1220, and A 2A AR binding was defined by specific binding displaced by 100 nmol/L ZM 241385. As shown in Figure 2 , incubation of rabbit brain or spleen membranes with Ϸ0.3 nmol/L [ 125 I]AB-MECA resulted in 90Ϯ1% and 74Ϯ1% specific binding, respectively. In brain tissue, Ϸ75% of the specific binding sites were A 1 , Ϸ12% were A 3 , and Ϸ13% were A 2A . In contrast, Ϸ25% of the specific binding sites in spleen were A 1 , Ϸ70% were A 3 , and Ͻ5% were A 2A . These data demonstrate that (1) (Figure 2) . In brain tissue, the CCPA and IB-MECA competition binding data fit best to a two-site binding model; the high-capacity binding site reflected binding to the A 1 AR. In spleen tissue when 500 nmol/L CPX and 100 nmol/L ZM 241825 were added to the assays, the data fit best to a single-site binding model reflecting binding to the A 3 AR. The IC 50 values of CCPA were calculated to be 0.32Ϯ0.06 nmol/L for the high-capacity binding site in brain (A 1 AR) and 50.1Ϯ18.1 nmol/L for the binding site in spleen (A 3 AR). The IC 50 values for IB-MECA were calculated to be 0.78Ϯ0.26 nmol/L for the single binding site in spleen (A 3 AR) and 10.1Ϯ2.2 nmol/L for the high-capacity binding site in brain (A 1 AR). These data demonstrate that CCPA binds selectively to endogenously expressed rabbit A 1 ARs (Ϸ160-fold selective) and that IB-MECA binds potently and with moderate selectivity (Ϸ13-fold selective) to endogenously expressed rabbit A 3 ARs. These results are similar to those obtained with CCPA and IB-MECA in binding studies using recombinant rabbit ARs expressed in HEK 293 cells (see Table) . 
Binding Studies
Detection of A 1 AR and A 3 AR Message by RT-PCR
No bands corresponding to the A 1 AR or A 3 AR were detected in heart tissue or isolated ventricular cardiomyocytes after RT-PCR, electrophoretic separation of the reactions through agarose gels, and staining with ethidium bromide. However, as shown in Figure 4 , distinct bands corresponding to the A 1 AR (310 bp) and A 3 AR (415 bp) were detected in both heart tissue and isolated cardiomyocytes after Southern blotting of the RT-PCR reactions and probing with A 1 AR-or A 3 AR-specific cDNA radioprobes. These results suggest that both A 1 AR and A 3 AR mRNAs are expressed in whole heart tissue as well as ventricular cardiomyocytes. Note that no bands were detected in negative control samples in which water was included in the RT-PCR reactions instead of RNA, excluding the possibility that the reactions were contaminated with foreign DNA. 
Delayed Cardioprotection by CCPA and IB-MECA in Conscious Rabbits
Exclusions Of the 129 rabbits instrumented for the studies of myocardial infarction, 26 were excluded because of ventricular fibrillation, technical problems, or a small risk region (Ͻ10% of left ventricular weight; see Table 1 in the online data supplement, available at http://www.circresaha.org).
Hemodynamic Variables on Day 1
Hemodynamic data for groups II, III, IVa, IVb, V, and VI on day 1 are presented in Figure 5 . At baseline, heart rate and mean arterial blood pressure were similar in all of the treatment groups (which ranged from 241 to 255 bpm and 74 to 82 mm Hg, respectively). In group II, administration of CCPA (100 g/kg) produced a transient reduction in heart rate and mean arterial blood pressure (maximal decreases of 24% and 14%, respectively). In group III, administration of 100 g/kg CGS 21680 increased heart rate by 29% and reduced mean arterial blood pressure by 17%. In group IVb, administration of IB-MECA at 300 g/kg caused an 11% decrease in heart rate but did not cause any appreciable changes in mean arterial blood pressure. However, IB-MECA at a dose of 100 g/kg (group IVb) did not influence either hemodynamic parameter. In group V and VI in which 100 g/kg CCPA and 300 g/kg IB-MECA were administered in animals treated concurrently with the A 1 AR antagonist N-0861, there were no appreciable changes in heart rate or blood pressure at any time, indicating that N-0861 completely blocked the hemodynamic actions of CCPA and IB-MECA.
Heart Rate on Day 2
There were no significant differences in heart rate among any of the groups during the 30-minute coronary occlusion or during the 72-hour reperfusion period, except for an Ϸ20% decrease in heart rate in all of the groups of rabbits treated with L-NA (see Table 2 in the online data supplement).
Region at Risk and Infarct Size
There were no significant differences among the groups with respect to the weight of the region at risk (which ranged from 15.8% to 20.1% of the left ventricle; see Table 3 in the online data supplement), indicating that this important determinant of infarct size is similar among the treatment groups. However, the average infarct size was 33% smaller in group II (CCPA 100 g/kg group), 44% smaller in the group IVa (IB-MECA 100 g/kg group), and 40% smaller in group IVb (IB-MECA 300 g/kg group) compared with the control group (38.3Ϯ4.1%, 33.7Ϯ4.9%, and 31.8Ϯ2.9% versus 56.4Ϯ4.0% of the risk region, respectively), indicating that both CCPA and IB-MECA (the latter even at a hemodynamically inert dose of 100 g/kg) elicited protection against infarction 24 hours later ( Figure 6 ). The average infarct size in group III (CGS 21680 100 g/kg group; 61.4Ϯ5.5%) did not differ from the control group, indicating that activation of A 2A ARs does not produce late PC against infarction. In group V (CCPA 100 g/kgϩN-0861 group), infarct size (59.8Ϯ3.8%) was indistinguishable from that measured in the control group and significantly larger than that measured in the CCPA group (Figure 6 ), indicating that N-0681 completely blocked the infarct-sparing effect of CCPA pretreatment. In group VI (IB-MECA 300 g/kgϩN-0861), infarct size (41.8Ϯ1.9%) was significantly smaller than that of the control group and was not significantly larger than that observed in the IB-MECA-pretreated group (Figure 6) . Thus, the same dose of N-0861 that blocked the infarct-sparing effect of CCPA failed to block the infarct-sparing effect of IB-MECA, implying that activation of A 3 ARs alone is sufficient to produce late PC against infarction.
Having found that both CCPA and IB-MECA induced late PC against infarction, we examined the effect of a nitric oxide synthase (NOS) inhibitor and an ATP-sensitive potassium (K ATP ) channel blocker on the cardioprotective responses. In group VII (CCPA 100 g/kgϩL-NA), infarct size (57.7Ϯ4.1%) was significantly greater than in group II (CCPA 100 g/kg) and essentially indistinguishable from controls (Figure 7) , indicating that L-NA abrogated the protective effect of CCPA. However, in group VIII (IB-MECA 300 g/kgϩL-NA) infarct size (36.6Ϯ3.4%) was significantly smaller than the control group and similar to that in group IVb (IB-MECA 300 g/kg), indicating that L-NA failed to block the protective effect of IB-MECA pretreatment. In groups X (CCPA 100 g/kgϩ5-HD) and XI (IB-MECA 300 g/kgϩ5-HD), infarct size (54.8Ϯ5.8% and 55.0Ϯ4.4%) was greater than in groups II (CCPA 100 g/kg) and IVb (IB-MECA 300 g/kg), respectively, and essentially indistinguishable from the control group (Figure 7) . Thus, administration of 5-HD on day 2 completely blocked the protection provided by pretreatment with either CCPA or IB-MECA. In groups IX (L-NA) and XII (5-HD), infarct size did not differ significantly from that in the control group (Figure 7) , indicating that administration of L-NA or 5-HD did not affect infarct size in vehicle-treated myocardium (55.0Ϯ4.4% and 52.0Ϯ5.5%, respectively).
Functional Recovery
The recovery of regional contractile function in the ischemicreperfused region was measured in groups I through IV. In keeping with the infarct size data, the recovery of systolic WTh was improved in rabbits pretreated with 100 g/kg CCPA, 100 g/kg IB-MECA, or 300 g/kg IB-MECA after 72 hours of reperfusion compared with that measured in the control group (3.5Ϯ3.9%, 5.5Ϯ9.4%, and 7.3Ϯ8.3% of baseline, respectively, versus Ϫ16.2Ϯ6.4% of baseline; PϽ0.05). In the CGS 21680-treated group, the recovery of systolic WTh at 72 hours was not significantly improved (Ϫ15.4Ϯ4.2% of baseline). 
Discussion
The results presented herein demonstrate that, in conscious rabbits, activation of either A 1 ARs or A 3 ARs (but not A 2A ARs) can induce late PC against infarction acting via distinct mechanisms. To the best of our knowledge, this is the first investigation to demonstrate that ARs can induce late PC in a conscious rabbit model. This is also the first investigation to demonstrate that the A 3 AR subtype, in addition to the A 1 AR subtype, is capable of triggering the development of late PC, that this effect of the A 3 AR is mediated by K ATP channels, and that NOS plays a differential role in A 1 ARversus A 3 AR-induced late PC.
The ability of AR agonists to induce late PC is controversial. Studies in barbital-anesthetized, open-chest rabbits support the concept that the A 1 AR agonist CCPA can induce late PC against myocardial infarction, 1 whereas studies in conscious rabbits suggest that CCPA cannot induce late PC against myocardial stunning. 2 One of the goals of the present investigation was to gain insights into this apparent discrepancy. Specifically, we sought to distinguish between two basic possibilities: (1) ARs can induce late PC against infarction but not late PC against myocardial stunning, or (2) the ability of AR agonists to induce late PC is dependent on the system in which they are studied. Our results provide evidence that the former hypothesis is correct. Using the same conscious rabbit model in which we previously observed that CCPA did not induce late PC against myocardial stunning, 2 we found that the same dose of CCPA induced late PC against myocardial infarction ( Figure 6 ). To the best of our knowledge, this is the first identification of a late PC stimulus that provides selective protection against a specific type of ischemic injury. Our results imply that there are important differences between the mechanism of late PC against myocardial stunning and late PC against infarction.
A second major goal of the present investigation was to determine whether the A 3 AR is capable of inducing late PC against infarction. Our approach was to compare the effects of CCPA to those of the recently characterized A 3 AR agonist IB-MECA. 14 We found that IB-MECA, at a dose of 300 g/kg, produced reductions in infarct size that were equivalent in magnitude to those elicited by CCPA (Figure 6 ), suggesting that the A 3 AR is also capable of inducing late PC against infarction. These results, however, must be interpreted with caution, because IB-MECA at a dose of 300 g/kg produced a modest decrease in heart rate ( Figure 5 ). This finding, coupled with the results of our in vitro radioligand binding studies showing that IB-MECA is only 13-to 21-fold more potent at binding to rabbit A 3 ARs compared with rabbit A 1 ARs (Table and Figure 2 ), raises the possibility that IB-MECA may have induced late PC not by interacting with A 3 ARs, but rather through nonspecific interactions with the A 1 AR. This possibility cannot be addressed using an A 3 AR-selective inhibitor because no antagonist is currently available that selectively inhibits rabbit A 3 ARs (Table) . Therefore, we performed two additional sets of experiments. First, we administered IB-MECA or CCPA in the presence of the A 1 AR antagonist N-0861 given at a dose predicted to produce blood levels (20 to 50 mol/L) 15 that do not block the A 3 AR. The finding that N-0861 blocked the actions of CCPA against infarction but not those of IB-MECA ( Figure  6 ) demonstrates that IB-MECA is capable of eliciting delayed cardioprotection through a mechanism independent of the A 1 AR, thereby implicating the involvement of the A 3 AR. Second, we administered IB-MECA at a lower dose (100 g/kg), which had no effect on heart rate ( Figure 5 ), indicating that it did not activate A 1 ARs. The finding that this lower dose of IB-MECA exerted a robust delayed cardioprotective action (Figure 6 ) further corroborates the conclusion that activation of A 3 ARs in itself induces late PC, indepen- dent of A 1 AR activation. The possibility that IB-MECA produced late PC by acting through A 2A ARs can be excluded because the selective A 2A AR agonist CGS 21680 did not reduce infarct size ( Figure 6 ). We can also exclude the possibility that IB-MECA acted through A 2B ARs, because it has extremely low affinity for this receptor subtype. 16 Thus, our results indicate that, similar to early PC, the late phase of PC can also be induced by activation of A 3 ARs.
Although current data indicate that A 3 ARs can induce both phases of PC, in recent in vivo studies we have observed that mice with genetic disruption of A 3 ARs exhibit infarcts that are smaller than those in wild-type mice, 17 raising the interesting possibility that A 3 ARs may actually play an injurious role during acute myocardial ischemia in this species. These observations are not in conflict with the idea that A 3 ARs can trigger PC, since the role of A 3 ARs in modulating injury during acute myocardial ischemia is distinct from their role in eliciting PC before ischemia. It is also important to keep in mind that the findings obtained with A 3 AR knockout mice need to be confirmed with the use of A 3 AR-selective antagonists, because chronic disruption of these receptors may produce compensatory changes in other genes and/or signaling pathways resulting in protection from ischemic injury. In addition, there are marked differences in the properties and tissue expression of A 3 ARs among species, 12 such that observations in mice should not be extrapolated to rabbits.
We also investigated the mechanisms by which CCPA and IB-MECA induce the delayed cardioprotection against infarction. We have previously found that both the anti-stunning and anti-infarct effects of ischemia-induced late PC are mediated by increased activity of NOS, specifically, the inducible isoform of NOS (iNOS). 18 Additional studies have demonstrated that the cardioprotective effects of CCPAinduced late PC can be blocked by inhibitors of the K ATP channel and are absent in iNOS knockout mice. 19, 20 Based on these observations, we hypothesized that late PC induced by both CCPA and IB-MECA is also the result of increased NOS activity and increased function of K ATP channels. We found that the nonselective NOS inhibitor L-NA and the K ATP channel antagonist 5-HD completely abrogated the protective effects of CCPA when they were administered immediately before the 30-minute coronary occlusion on day 2 ( Figure 7) . On the other hand, IB-MECA-induced late PC was not blocked by L-NA but was completely abrogated by 5-HD ( Figure 7 ). It appears, therefore, that CCPA-induced late PC against infarction involves a mechanism similar to that of ischemia-induced late PC 18 ; that is, cardioprotection is due to enhanced production of NO via induction of NOS and enhanced function of K ATP channels. IB-MECA-induced late PC also appears to utilize a mechanism requiring K ATP channels; however, upregulation of NOS is not a necessary component. Thus, the results suggest that the mechanisms by which A 1 ARs and A 3 ARs induce late PC against infarction involve different pathways that ultimately converge on the K ATP channel.
Elucidation of the mechanisms by which ARs modulate PC requires knowledge of the cell types within the heart that express A 1 ARs and A 3 ARs. It is well established that A 1 ARs coupled to inhibition of adenylyl cyclase via G i/o proteins are expressed in cardiomyocytes in both atria and ventricles. These receptors classically are known to counteract the positive inotropic actions of catecholamines. 21 Recent data indicate that cardiac A 1 ARs induce delayed PC via signaling pathways involving protein kinase C, tyrosine kinases, and mitogen-activated/stress-activated protein kinases. 22 With regard to the A 3 AR, however, little is known regarding the specific cell types within the heart that express this receptor subtype. Strickler et al 10 recently demonstrated that A 3 ARs are expressed in cultured embryonic chicken cardiomyocytes and that activation of these receptors produces protection against cell death induced by simulated ischemia and reperfusion. Thus, it is possible that cardiomyocytes also express A 3 ARs, which may induce PC via similar signaling pathways as the A 1 AR. This hypothesis is supported by the results of the present investigation in which we were able to detect A 3 AR mRNA in adult rabbit cardiomyocytes by RT-PCR analysis ( Figure 4 ). The cell types within the heart that express A 3 ARs may not be limited to cardiomyocytes, however. For example, in other tissues, the A 3 AR is known to be expressed in resident leukocytes such as macrophages and mast cells. 12 A 3 ARs have also been suggested to be expressed in vascular smooth muscle cells and endothelial cells. 23 Based on these observations, it remains possible that A 3 AR agonists may elicit PC through the release of mediators from nonmyocytic cells. Clearly, additional studies of A 3 ARs in the heart are warranted.
In conclusion, the present study demonstrates that activation of ARs induces a long-lasting cardioprotective effect in conscious rabbits, suggesting that AR agonists could be used to maintain patients in a protracted preconditioned state. Our results further demonstrate that selective agonists of either A 1 ARs or A 3 ARs can induce a late PC effect. Because A 3 AR agonists can provide protection with minimal hemodynamic effects, these results imply that targeting the A 3 AR could be a novel and useful approach to the protection of the ischemic myocardium. Finally, the present study elucidates the molecular mechanisms of A 1 AR-and A 3 AR-induced late PC by identifying common and differential roles for the K ATP channel and NOS, respectively, in theses two forms of delayed cardioprotection.
